The clinical efficacy of mTOR inhibitors in lung carcinoids – and neuroendocrine cancer in general - might be improved by identifying i) the molecular mechanisms of mTOR pathway activation in cancer cells, and - as a consequence – ii) predictive markers of response to mTOR inhibitors. Here, MTOR is linked to neuroendocrine carcinoma.